重组人促红素-β注射液联合常规治疗在脑损伤早产儿中的应用效果  

Effects of recombinant human erythropoietin-βinjection combined with conventional treatment on premature infants with brain injury

作　　者：杨柳[1] 孙丽丽[1] 宋红丽[1] YANG Liu;SUN Lili;SONG Hongli(Department of Neonatology of Pingyu County People’s Hospital,Zhumadian 463400 Henan,China)

机构地区：[1]平舆县人民医院新生儿科,河南驻马店463400

出　　处：《中国民康医学》2024年第5期73-75,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察重组人促红素-β注射液联合常规治疗在脑损伤早产儿中的应用效果。方法:回顾性分析2020年2月至2022年2月该院收治的86例脑损伤早产儿的临床资料,按治疗方案不同分为研究组和对照组各43例。对照组采用常规治疗,研究组在对照组基础上予以重组人促红素-β注射液治疗,比较两组治疗总有效率、新生儿行为神经测定(NBNA)评分、血气分析指标[动脉血二氧化碳分压(PaCO_(2))、pH]水平和血清细胞因子[缺氧诱导因子-1α(HIF-1α)、神经元特异性烯醇化酶(NSE)、中枢神经特异性蛋白(S100β)、髓鞘碱性蛋白(MBP)]水平。结果:研究组治疗总有效率为93.02%,明显高于对照组的74.42%,差异有统计学意义(P<0.05);治疗后,两组PaCO_(2)、HIF-1α、NSE、S100β、MBP水平低于治疗前,且研究组低于对照组,两组pH水平、NBNA评分高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0.05)。结论:重组人促红素-β注射液联合常规治疗应用于脑损伤早产儿可提高治疗总有效率和NBNA评分,改善血气分析指标水平,以及降低血清细胞因子水平,效果优于单纯常规治疗。Objective:To observe effects of recombinant human erythropoietin-βinjection combined with conventional treatment on premature infants with brain injury.Methods:The clinical data of 86 premature infants with brain injury admitted to this hospital from February 2020 to February 2022 were retrospectively analyzed.According to different treatment options,they were divided into study group and control group,43 cases in each group.The control group was treated with conventional treatment,while the study group was treated with recombinant human erythropoietin-βinjection on the basis of that of the control group.The total effective rate of treatment,the neonatal behavioral neurological assessment(NBNA)score,the blood gas analysis indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),pH]levels,and the serum cytokines[hypoxia inducible factor-1α(HIF-1α),neuron-specific enolase(NSE),central nervous system specific protein(S100β),myelin basic protein(MBP)]were compared between the two groups.Results:The total effective rate of the study group was 93.02%,which was significantly higher than 74.42%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PaCO_(2),HIF-1α,NSE,S100βand MBP in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the pH levels and the NBNA scores of the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;and the differences were statistically significant(P<0.05).Conclusions:Recombinant human erythropoietin-βinjection combined with conventional treatment for the premature infants with brain injury can improve the total effective rate of treatment and the NBNA scores,improve the levels of blood gas analysis indexes,and reduce the levels of serum cytokines.Moreover,it is superior to single conventional treatment.

关 键 词：重组人促红素-β注射液 早产儿 脑损伤 血气分析 细胞因子 NBNA评分 

分 类 号：R722.6[医药卫生—儿科]